|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Skandalakis LJ, Rowe JS Jr, Gray SW and
Skandalakis JE: Surgical embryology and anatomy of the pancreas.
Surg Clin North Am. 73:661–697. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vidal C, Rauly I, Zeggari M, Delesque N,
Esteve JP, Saint-Laurent N, Vaysse N and Susini C: Up-regulation of
somatostatin receptors by epidermal growth factor and gastrin in
pancreatic cancer cells. Mol Pharmacol. 46:97–104. 1994.PubMed/NCBI
|
|
8
|
Miller DM, Thomas SD, Islam A, Muench D
and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res.
18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blum R and Kloog Y: Metabolism addiction
in pancreatic cancer. Cell Death Dis. 5:e10652014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goldberg MS and Sharp PA: Pyruvate kinase
M2-specific siRNA induces apoptosis and tumor regression. J Exp
Med. 209:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim YS and Milner JA: Bioactive food
components and cancer-specific metabonomic profiles. J Biomed
Biotechnol. 2011:7212132011. View Article : Google Scholar
|
|
13
|
Chao EC and Henry RR: SGLT2 inhibition-a
novel strategy for diabetes treatment. Nat Rev Drug Discov.
9:551–559. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kaji K, Nishimura N, Seki K, Sato S,
Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya
K, et al: Sodium glucose cotransporter 2 inhibitor canagliflozin
attenuates liver cancer cell growth and angiogenic activity by
inhibiting glucose uptake. Int J Cancer. 142:1712–1722. 2018.
View Article : Google Scholar
|
|
15
|
Shiba K, Tsuchiya K, Komiya C, Miyachi Y,
Mori K, Shimazu N, Yamaguchi S, Ogasawara N, Katoh M, Itoh M, et
al: Canagliflozin, an SGLT2 inhibitor, attenuates the development
of hepatocellular carcinoma in a mouse model of human NASH. Sci
Rep. 8:23622018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Jiang H, Fan D, Zhou G, Li X and Deng H:
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis
of human nasopharyngeal carcinoma in vitro and in vivo. J Exp Clin
Cancer Res. 29:342010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chu LC, Goggins MG and Fishman EK:
Diagnosis and detection of pancreatic Cancer. Cancer J. 23:333–342.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dreyer SB, Chang DK, Bailey P and Biankin
AV: Pancreatic cancer genomes: Implications for clinical management
and therapeutic development. Clin Cancer Res. 23:1638–1646. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le A, Rajeshkumar NV, Maitra A and Dang
CV: Conceptual framework for cutting the pancreatic cancer fuel
supply. Clin Cancer Res. 18:4285–4290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sousa CM and Kimmelman AC: The complex
landscape of pancreatic cancer metabolism. Carcinogenesis.
35:1441–1450. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinrich S and Lang H: Neoadjuvant therapy
of pancreatic Cancer: Definitions and benefits. Int J Mol Sci.
18:16222017. View Article : Google Scholar :
|
|
26
|
Garber K: Energy deregulation: Licensing
tumors to grow. Science. 312:1158–1159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoon SO, Jeon TJ, Park JS, Ryu YH, Lee JH,
Yoo JS, Kim JK, Yoon DS and Oh EJ: Analysis of the roles of glucose
transporter 1 and hexokinase 2 in the metabolism of glucose by
extrahepatic bile duct cancer cells. Clin Nucl Med. 40:e178–e182.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang TB, Zhao Y, Tong ZX and Guan YF:
Inhibition of glucose-transporter 1 (GLUT-1) expression reversed
Warburg effect in gastric cancer cell MKN45. Int J Clin Exp Med.
8:2423–2428. 2015.PubMed/NCBI
|
|
29
|
Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T,
Huang KJ, Yao M and Huang C: Expression of hypoxia-inducible
factor-1 alpha and associated proteins in pancreatic ductal
adenocarcinoma and their impact on prognosis. Int J Oncol.
30:1359–1367. 2007.PubMed/NCBI
|
|
30
|
Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D
and Lou W: Lactate dehydrogenase A is overexpressed in pancreatic
cancer and promotes the growth of pancreatic cancer cells. Tumor
Biol. 34:1523–1530. 2013. View Article : Google Scholar
|
|
31
|
Li X, Wenes M, Romero P, Huang SC, Fendt
SM and Ho PC: Navigating metabolic pathways to enhance antitumour
immunity and immunotherapy. Nat Rev Clin Oncol. 16:425–441. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang V, Davis DA, Haque M, Huang LE and
Yarchoan R: Differential gene up-regulation by hypoxia-inducible
factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells.
Cancer Res. 65:3299–3306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gordan JD, Bertout JA, Hu CJ, Diehl JA and
Simon MC: HIF-2alpha promotes hypoxic cell proliferation by
enhancing c-myc transcriptional activity. Cancer Cell. 11:335–347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen C, Pore N, Behrooz A, Ismail-Beigi F
and Maity A: Regulation of glut1 mRNA by hypoxia-inducible
factor-1. Interaction between H-ras and hypoxia. J Biol Chem.
276:9519–9525. 2001. View Article : Google Scholar
|
|
35
|
Firth JD, Ebert BL and Ratcliffe PJ:
Hypoxic regulation of lactate dehydrogenase A. Interaction between
hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem.
270:21021–21027. 1995. View Article : Google Scholar : PubMed/NCBI
|
